Updated interim efficacy analysis and long-term safety of abiraterone acetate in metastatic castration-resistant prostate cancer patients without prior chemotherapy (COU-AA-302).
Identifieur interne : 003365 ( PubMed/Corpus ); précédent : 003364; suivant : 003366Updated interim efficacy analysis and long-term safety of abiraterone acetate in metastatic castration-resistant prostate cancer patients without prior chemotherapy (COU-AA-302).
Auteurs : Dana E. Rathkopf ; Matthew R. Smith ; Johann S. De Bono ; Christopher J. Logothetis ; Neal D. Shore ; Paul De Souza ; Karim Fizazi ; Peter F A. Mulders ; Paul Mainwaring ; John D. Hainsworth ; Tomasz M. Beer ; Scott North ; Yves Fradet ; Hendrik Van Poppel ; Joan Carles ; Thomas W. Flaig ; Eleni Efstathiou ; Evan Y. Yu ; Celestia S. Higano ; Mary-Ellen Taplin ; Thomas W. Griffin ; Mary B. Todd ; Margaret K. Yu ; Youn C. Park ; Thian Kheoh ; Eric J. Small ; Howard I. Scher ; Arturo Molina ; Charles J. Ryan ; Fred SaadSource :
- European urology [ 1873-7560 ] ; 2014.
English descriptors
- KwdEn :
- Abiraterone Acetate, Aged, Androstenes (administration & dosage), Androstenes (adverse effects), Antineoplastic Agents, Hormonal (administration & dosage), Antineoplastic Agents, Hormonal (adverse effects), Antineoplastic Combined Chemotherapy Protocols (adverse effects), Antineoplastic Combined Chemotherapy Protocols (therapeutic use), Cytochrome P-450 Enzyme Inhibitors (administration & dosage), Cytochrome P-450 Enzyme Inhibitors (adverse effects), Disease Progression, Disease-Free Survival, Double-Blind Method, Drug Administration Schedule, Humans, Kaplan-Meier Estimate, Male, Middle Aged, Neoplasm Metastasis, Neoplasms, Hormone-Dependent (drug therapy), Neoplasms, Hormone-Dependent (enzymology), Neoplasms, Hormone-Dependent (mortality), Neoplasms, Hormone-Dependent (pathology), Prednisone (administration & dosage), Proportional Hazards Models, Prostatic Neoplasms, Castration-Resistant (drug therapy), Prostatic Neoplasms, Castration-Resistant (enzymology), Prostatic Neoplasms, Castration-Resistant (mortality), Prostatic Neoplasms, Castration-Resistant (pathology), Risk Factors, Steroid 17-alpha-Hydroxylase (antagonists & inhibitors), Steroid 17-alpha-Hydroxylase (metabolism), Time Factors, Treatment Outcome.
- MESH :
- chemical , administration & dosage : Androstenes, Antineoplastic Agents, Hormonal, Cytochrome P-450 Enzyme Inhibitors, Prednisone.
- chemical , adverse effects : Androstenes, Antineoplastic Agents, Hormonal, Cytochrome P-450 Enzyme Inhibitors.
- chemical , antagonists & inhibitors : Steroid 17-alpha-Hydroxylase.
- chemical , metabolism : Steroid 17-alpha-Hydroxylase.
- chemical : Abiraterone Acetate.
- adverse effects : Antineoplastic Combined Chemotherapy Protocols.
- drug therapy : Neoplasms, Hormone-Dependent, Prostatic Neoplasms, Castration-Resistant.
- enzymology : Neoplasms, Hormone-Dependent, Prostatic Neoplasms, Castration-Resistant.
- mortality : Neoplasms, Hormone-Dependent, Prostatic Neoplasms, Castration-Resistant.
- pathology : Neoplasms, Hormone-Dependent, Prostatic Neoplasms, Castration-Resistant.
- therapeutic use : Antineoplastic Combined Chemotherapy Protocols.
- Aged, Disease Progression, Disease-Free Survival, Double-Blind Method, Drug Administration Schedule, Humans, Kaplan-Meier Estimate, Male, Middle Aged, Neoplasm Metastasis, Proportional Hazards Models, Risk Factors, Time Factors, Treatment Outcome.
Abstract
Abiraterone acetate (an androgen biosynthesis inhibitor) plus prednisone is approved for treating patients with metastatic castration-resistant prostate cancer (mCRPC). Study COU-AA-302 evaluated abiraterone acetate plus prednisone versus prednisone alone in mildly symptomatic or asymptomatic patients with progressive mCRPC without prior chemotherapy.
DOI: 10.1016/j.eururo.2014.02.056
PubMed: 24647231
Links to Exploration step
pubmed:24647231Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Updated interim efficacy analysis and long-term safety of abiraterone acetate in metastatic castration-resistant prostate cancer patients without prior chemotherapy (COU-AA-302).</title><author><name sortKey="Rathkopf, Dana E" sort="Rathkopf, Dana E" uniqKey="Rathkopf D" first="Dana E" last="Rathkopf">Dana E. Rathkopf</name><affiliation><nlm:affiliation>Memorial Sloan-Kettering Cancer Center and Weill Cornell Medical College, New York, NY, USA. Electronic address: rathkopd@mskcc.org.</nlm:affiliation></affiliation></author><author><name sortKey="Smith, Matthew R" sort="Smith, Matthew R" uniqKey="Smith M" first="Matthew R" last="Smith">Matthew R. Smith</name><affiliation><nlm:affiliation>Harvard Medical School and Massachusetts General Hospital, Boston, MA, USA.</nlm:affiliation></affiliation></author><author><name sortKey="De Bono, Johann S" sort="De Bono, Johann S" uniqKey="De Bono J" first="Johann S" last="De Bono">Johann S. De Bono</name><affiliation><nlm:affiliation>The Institute of Cancer Research and Royal Marsden NHS Foundation Trust, Sutton, Surrey, UK.</nlm:affiliation></affiliation></author><author><name sortKey="Logothetis, Christopher J" sort="Logothetis, Christopher J" uniqKey="Logothetis C" first="Christopher J" last="Logothetis">Christopher J. Logothetis</name><affiliation><nlm:affiliation>MD Anderson Cancer Center, Houston, TX, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Shore, Neal D" sort="Shore, Neal D" uniqKey="Shore N" first="Neal D" last="Shore">Neal D. Shore</name><affiliation><nlm:affiliation>Carolina Urologic Research Center, Atlantic Urology Clinics, Myrtle Beach, SC, USA.</nlm:affiliation></affiliation></author><author><name sortKey="De Souza, Paul" sort="De Souza, Paul" uniqKey="De Souza P" first="Paul" last="De Souza">Paul De Souza</name><affiliation><nlm:affiliation>University of Western Sydney School of Medicine, Penrith, Australia.</nlm:affiliation></affiliation></author><author><name sortKey="Fizazi, Karim" sort="Fizazi, Karim" uniqKey="Fizazi K" first="Karim" last="Fizazi">Karim Fizazi</name><affiliation><nlm:affiliation>Institut Gustave Roussy, University of Paris Sud, Villejuif, France.</nlm:affiliation></affiliation></author><author><name sortKey="Mulders, Peter F A" sort="Mulders, Peter F A" uniqKey="Mulders P" first="Peter F A" last="Mulders">Peter F A. Mulders</name><affiliation><nlm:affiliation>Radboud University Medical Centre, Nijmegen, The Netherlands.</nlm:affiliation></affiliation></author><author><name sortKey="Mainwaring, Paul" sort="Mainwaring, Paul" uniqKey="Mainwaring P" first="Paul" last="Mainwaring">Paul Mainwaring</name><affiliation><nlm:affiliation>Hematology & Oncology Clinics of Australia, Brisbane, Australia.</nlm:affiliation></affiliation></author><author><name sortKey="Hainsworth, John D" sort="Hainsworth, John D" uniqKey="Hainsworth J" first="John D" last="Hainsworth">John D. Hainsworth</name><affiliation><nlm:affiliation>Sarah Cannon Research Institute, Nashville, TN, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Beer, Tomasz M" sort="Beer, Tomasz M" uniqKey="Beer T" first="Tomasz M" last="Beer">Tomasz M. Beer</name><affiliation><nlm:affiliation>Oregon Health & Science University Knight Cancer Institute, Portland, OR, USA.</nlm:affiliation></affiliation></author><author><name sortKey="North, Scott" sort="North, Scott" uniqKey="North S" first="Scott" last="North">Scott North</name><affiliation><nlm:affiliation>Cross Cancer Institute, Edmonton, Alberta, Canada.</nlm:affiliation></affiliation></author><author><name sortKey="Fradet, Yves" sort="Fradet, Yves" uniqKey="Fradet Y" first="Yves" last="Fradet">Yves Fradet</name><affiliation><nlm:affiliation>Laval University, Québec City, Québec, Canada.</nlm:affiliation></affiliation></author><author><name sortKey="Van Poppel, Hendrik" sort="Van Poppel, Hendrik" uniqKey="Van Poppel H" first="Hendrik" last="Van Poppel">Hendrik Van Poppel</name><affiliation><nlm:affiliation>University Hospital Leuven, Leuven, Belgium.</nlm:affiliation></affiliation></author><author><name sortKey="Carles, Joan" sort="Carles, Joan" uniqKey="Carles J" first="Joan" last="Carles">Joan Carles</name><affiliation><nlm:affiliation>Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain.</nlm:affiliation></affiliation></author><author><name sortKey="Flaig, Thomas W" sort="Flaig, Thomas W" uniqKey="Flaig T" first="Thomas W" last="Flaig">Thomas W. Flaig</name><affiliation><nlm:affiliation>University of Colorado Cancer Center and University of Colorado School of Medicine, Aurora, CO, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Efstathiou, Eleni" sort="Efstathiou, Eleni" uniqKey="Efstathiou E" first="Eleni" last="Efstathiou">Eleni Efstathiou</name><affiliation><nlm:affiliation>MD Anderson Cancer Center, Houston, TX, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Yu, Evan Y" sort="Yu, Evan Y" uniqKey="Yu E" first="Evan Y" last="Yu">Evan Y. Yu</name><affiliation><nlm:affiliation>University of Washington, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Higano, Celestia S" sort="Higano, Celestia S" uniqKey="Higano C" first="Celestia S" last="Higano">Celestia S. Higano</name><affiliation><nlm:affiliation>University of Washington, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Taplin, Mary Ellen" sort="Taplin, Mary Ellen" uniqKey="Taplin M" first="Mary-Ellen" last="Taplin">Mary-Ellen Taplin</name><affiliation><nlm:affiliation>Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Griffin, Thomas W" sort="Griffin, Thomas W" uniqKey="Griffin T" first="Thomas W" last="Griffin">Thomas W. Griffin</name><affiliation><nlm:affiliation>Janssen Research & Development, Los Angeles, CA, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Todd, Mary B" sort="Todd, Mary B" uniqKey="Todd M" first="Mary B" last="Todd">Mary B. Todd</name><affiliation><nlm:affiliation>Janssen Research & Development, Raritan, NJ, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Yu, Margaret K" sort="Yu, Margaret K" uniqKey="Yu M" first="Margaret K" last="Yu">Margaret K. Yu</name><affiliation><nlm:affiliation>Janssen Research & Development, Los Angeles, CA, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Park, Youn C" sort="Park, Youn C" uniqKey="Park Y" first="Youn C" last="Park">Youn C. Park</name><affiliation><nlm:affiliation>Janssen Research & Development, Raritan, NJ, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Kheoh, Thian" sort="Kheoh, Thian" uniqKey="Kheoh T" first="Thian" last="Kheoh">Thian Kheoh</name><affiliation><nlm:affiliation>Janssen Research & Development, Los Angeles, CA, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Small, Eric J" sort="Small, Eric J" uniqKey="Small E" first="Eric J" last="Small">Eric J. Small</name><affiliation><nlm:affiliation>Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Scher, Howard I" sort="Scher, Howard I" uniqKey="Scher H" first="Howard I" last="Scher">Howard I. Scher</name><affiliation><nlm:affiliation>Memorial Sloan-Kettering Cancer Center and Weill Cornell Medical College, New York, NY, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Molina, Arturo" sort="Molina, Arturo" uniqKey="Molina A" first="Arturo" last="Molina">Arturo Molina</name><affiliation><nlm:affiliation>Janssen Research & Development, Menlo Park, CA, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Ryan, Charles J" sort="Ryan, Charles J" uniqKey="Ryan C" first="Charles J" last="Ryan">Charles J. Ryan</name><affiliation><nlm:affiliation>Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Saad, Fred" sort="Saad, Fred" uniqKey="Saad F" first="Fred" last="Saad">Fred Saad</name><affiliation><nlm:affiliation>CRCHUM, University of Montréal, Montréal, Québec, Canada.</nlm:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2014">2014</date><idno type="RBID">pubmed:24647231</idno><idno type="pmid">24647231</idno><idno type="doi">10.1016/j.eururo.2014.02.056</idno><idno type="wicri:Area/PubMed/Corpus">003365</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">003365</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Updated interim efficacy analysis and long-term safety of abiraterone acetate in metastatic castration-resistant prostate cancer patients without prior chemotherapy (COU-AA-302).</title><author><name sortKey="Rathkopf, Dana E" sort="Rathkopf, Dana E" uniqKey="Rathkopf D" first="Dana E" last="Rathkopf">Dana E. Rathkopf</name><affiliation><nlm:affiliation>Memorial Sloan-Kettering Cancer Center and Weill Cornell Medical College, New York, NY, USA. Electronic address: rathkopd@mskcc.org.</nlm:affiliation></affiliation></author><author><name sortKey="Smith, Matthew R" sort="Smith, Matthew R" uniqKey="Smith M" first="Matthew R" last="Smith">Matthew R. Smith</name><affiliation><nlm:affiliation>Harvard Medical School and Massachusetts General Hospital, Boston, MA, USA.</nlm:affiliation></affiliation></author><author><name sortKey="De Bono, Johann S" sort="De Bono, Johann S" uniqKey="De Bono J" first="Johann S" last="De Bono">Johann S. De Bono</name><affiliation><nlm:affiliation>The Institute of Cancer Research and Royal Marsden NHS Foundation Trust, Sutton, Surrey, UK.</nlm:affiliation></affiliation></author><author><name sortKey="Logothetis, Christopher J" sort="Logothetis, Christopher J" uniqKey="Logothetis C" first="Christopher J" last="Logothetis">Christopher J. Logothetis</name><affiliation><nlm:affiliation>MD Anderson Cancer Center, Houston, TX, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Shore, Neal D" sort="Shore, Neal D" uniqKey="Shore N" first="Neal D" last="Shore">Neal D. Shore</name><affiliation><nlm:affiliation>Carolina Urologic Research Center, Atlantic Urology Clinics, Myrtle Beach, SC, USA.</nlm:affiliation></affiliation></author><author><name sortKey="De Souza, Paul" sort="De Souza, Paul" uniqKey="De Souza P" first="Paul" last="De Souza">Paul De Souza</name><affiliation><nlm:affiliation>University of Western Sydney School of Medicine, Penrith, Australia.</nlm:affiliation></affiliation></author><author><name sortKey="Fizazi, Karim" sort="Fizazi, Karim" uniqKey="Fizazi K" first="Karim" last="Fizazi">Karim Fizazi</name><affiliation><nlm:affiliation>Institut Gustave Roussy, University of Paris Sud, Villejuif, France.</nlm:affiliation></affiliation></author><author><name sortKey="Mulders, Peter F A" sort="Mulders, Peter F A" uniqKey="Mulders P" first="Peter F A" last="Mulders">Peter F A. Mulders</name><affiliation><nlm:affiliation>Radboud University Medical Centre, Nijmegen, The Netherlands.</nlm:affiliation></affiliation></author><author><name sortKey="Mainwaring, Paul" sort="Mainwaring, Paul" uniqKey="Mainwaring P" first="Paul" last="Mainwaring">Paul Mainwaring</name><affiliation><nlm:affiliation>Hematology & Oncology Clinics of Australia, Brisbane, Australia.</nlm:affiliation></affiliation></author><author><name sortKey="Hainsworth, John D" sort="Hainsworth, John D" uniqKey="Hainsworth J" first="John D" last="Hainsworth">John D. Hainsworth</name><affiliation><nlm:affiliation>Sarah Cannon Research Institute, Nashville, TN, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Beer, Tomasz M" sort="Beer, Tomasz M" uniqKey="Beer T" first="Tomasz M" last="Beer">Tomasz M. Beer</name><affiliation><nlm:affiliation>Oregon Health & Science University Knight Cancer Institute, Portland, OR, USA.</nlm:affiliation></affiliation></author><author><name sortKey="North, Scott" sort="North, Scott" uniqKey="North S" first="Scott" last="North">Scott North</name><affiliation><nlm:affiliation>Cross Cancer Institute, Edmonton, Alberta, Canada.</nlm:affiliation></affiliation></author><author><name sortKey="Fradet, Yves" sort="Fradet, Yves" uniqKey="Fradet Y" first="Yves" last="Fradet">Yves Fradet</name><affiliation><nlm:affiliation>Laval University, Québec City, Québec, Canada.</nlm:affiliation></affiliation></author><author><name sortKey="Van Poppel, Hendrik" sort="Van Poppel, Hendrik" uniqKey="Van Poppel H" first="Hendrik" last="Van Poppel">Hendrik Van Poppel</name><affiliation><nlm:affiliation>University Hospital Leuven, Leuven, Belgium.</nlm:affiliation></affiliation></author><author><name sortKey="Carles, Joan" sort="Carles, Joan" uniqKey="Carles J" first="Joan" last="Carles">Joan Carles</name><affiliation><nlm:affiliation>Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain.</nlm:affiliation></affiliation></author><author><name sortKey="Flaig, Thomas W" sort="Flaig, Thomas W" uniqKey="Flaig T" first="Thomas W" last="Flaig">Thomas W. Flaig</name><affiliation><nlm:affiliation>University of Colorado Cancer Center and University of Colorado School of Medicine, Aurora, CO, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Efstathiou, Eleni" sort="Efstathiou, Eleni" uniqKey="Efstathiou E" first="Eleni" last="Efstathiou">Eleni Efstathiou</name><affiliation><nlm:affiliation>MD Anderson Cancer Center, Houston, TX, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Yu, Evan Y" sort="Yu, Evan Y" uniqKey="Yu E" first="Evan Y" last="Yu">Evan Y. Yu</name><affiliation><nlm:affiliation>University of Washington, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Higano, Celestia S" sort="Higano, Celestia S" uniqKey="Higano C" first="Celestia S" last="Higano">Celestia S. Higano</name><affiliation><nlm:affiliation>University of Washington, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Taplin, Mary Ellen" sort="Taplin, Mary Ellen" uniqKey="Taplin M" first="Mary-Ellen" last="Taplin">Mary-Ellen Taplin</name><affiliation><nlm:affiliation>Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Griffin, Thomas W" sort="Griffin, Thomas W" uniqKey="Griffin T" first="Thomas W" last="Griffin">Thomas W. Griffin</name><affiliation><nlm:affiliation>Janssen Research & Development, Los Angeles, CA, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Todd, Mary B" sort="Todd, Mary B" uniqKey="Todd M" first="Mary B" last="Todd">Mary B. Todd</name><affiliation><nlm:affiliation>Janssen Research & Development, Raritan, NJ, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Yu, Margaret K" sort="Yu, Margaret K" uniqKey="Yu M" first="Margaret K" last="Yu">Margaret K. Yu</name><affiliation><nlm:affiliation>Janssen Research & Development, Los Angeles, CA, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Park, Youn C" sort="Park, Youn C" uniqKey="Park Y" first="Youn C" last="Park">Youn C. Park</name><affiliation><nlm:affiliation>Janssen Research & Development, Raritan, NJ, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Kheoh, Thian" sort="Kheoh, Thian" uniqKey="Kheoh T" first="Thian" last="Kheoh">Thian Kheoh</name><affiliation><nlm:affiliation>Janssen Research & Development, Los Angeles, CA, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Small, Eric J" sort="Small, Eric J" uniqKey="Small E" first="Eric J" last="Small">Eric J. Small</name><affiliation><nlm:affiliation>Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Scher, Howard I" sort="Scher, Howard I" uniqKey="Scher H" first="Howard I" last="Scher">Howard I. Scher</name><affiliation><nlm:affiliation>Memorial Sloan-Kettering Cancer Center and Weill Cornell Medical College, New York, NY, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Molina, Arturo" sort="Molina, Arturo" uniqKey="Molina A" first="Arturo" last="Molina">Arturo Molina</name><affiliation><nlm:affiliation>Janssen Research & Development, Menlo Park, CA, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Ryan, Charles J" sort="Ryan, Charles J" uniqKey="Ryan C" first="Charles J" last="Ryan">Charles J. Ryan</name><affiliation><nlm:affiliation>Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Saad, Fred" sort="Saad, Fred" uniqKey="Saad F" first="Fred" last="Saad">Fred Saad</name><affiliation><nlm:affiliation>CRCHUM, University of Montréal, Montréal, Québec, Canada.</nlm:affiliation></affiliation></author></analytic><series><title level="j">European urology</title><idno type="eISSN">1873-7560</idno><imprint><date when="2014" type="published">2014</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Abiraterone Acetate</term><term>Aged</term><term>Androstenes (administration & dosage)</term><term>Androstenes (adverse effects)</term><term>Antineoplastic Agents, Hormonal (administration & dosage)</term><term>Antineoplastic Agents, Hormonal (adverse effects)</term><term>Antineoplastic Combined Chemotherapy Protocols (adverse effects)</term><term>Antineoplastic Combined Chemotherapy Protocols (therapeutic use)</term><term>Cytochrome P-450 Enzyme Inhibitors (administration & dosage)</term><term>Cytochrome P-450 Enzyme Inhibitors (adverse effects)</term><term>Disease Progression</term><term>Disease-Free Survival</term><term>Double-Blind Method</term><term>Drug Administration Schedule</term><term>Humans</term><term>Kaplan-Meier Estimate</term><term>Male</term><term>Middle Aged</term><term>Neoplasm Metastasis</term><term>Neoplasms, Hormone-Dependent (drug therapy)</term><term>Neoplasms, Hormone-Dependent (enzymology)</term><term>Neoplasms, Hormone-Dependent (mortality)</term><term>Neoplasms, Hormone-Dependent (pathology)</term><term>Prednisone (administration & dosage)</term><term>Proportional Hazards Models</term><term>Prostatic Neoplasms, Castration-Resistant (drug therapy)</term><term>Prostatic Neoplasms, Castration-Resistant (enzymology)</term><term>Prostatic Neoplasms, Castration-Resistant (mortality)</term><term>Prostatic Neoplasms, Castration-Resistant (pathology)</term><term>Risk Factors</term><term>Steroid 17-alpha-Hydroxylase (antagonists & inhibitors)</term><term>Steroid 17-alpha-Hydroxylase (metabolism)</term><term>Time Factors</term><term>Treatment Outcome</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Androstenes</term><term>Antineoplastic Agents, Hormonal</term><term>Cytochrome P-450 Enzyme Inhibitors</term><term>Prednisone</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Androstenes</term><term>Antineoplastic Agents, Hormonal</term><term>Cytochrome P-450 Enzyme Inhibitors</term></keywords><keywords scheme="MESH" type="chemical" qualifier="antagonists & inhibitors" xml:lang="en"><term>Steroid 17-alpha-Hydroxylase</term></keywords><keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Steroid 17-alpha-Hydroxylase</term></keywords><keywords scheme="MESH" type="chemical" xml:lang="en"><term>Abiraterone Acetate</term></keywords><keywords scheme="MESH" qualifier="adverse effects" xml:lang="en"><term>Antineoplastic Combined Chemotherapy Protocols</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Neoplasms, Hormone-Dependent</term><term>Prostatic Neoplasms, Castration-Resistant</term></keywords><keywords scheme="MESH" qualifier="enzymology" xml:lang="en"><term>Neoplasms, Hormone-Dependent</term><term>Prostatic Neoplasms, Castration-Resistant</term></keywords><keywords scheme="MESH" qualifier="mortality" xml:lang="en"><term>Neoplasms, Hormone-Dependent</term><term>Prostatic Neoplasms, Castration-Resistant</term></keywords><keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Neoplasms, Hormone-Dependent</term><term>Prostatic Neoplasms, Castration-Resistant</term></keywords><keywords scheme="MESH" qualifier="therapeutic use" xml:lang="en"><term>Antineoplastic Combined Chemotherapy Protocols</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Aged</term><term>Disease Progression</term><term>Disease-Free Survival</term><term>Double-Blind Method</term><term>Drug Administration Schedule</term><term>Humans</term><term>Kaplan-Meier Estimate</term><term>Male</term><term>Middle Aged</term><term>Neoplasm Metastasis</term><term>Proportional Hazards Models</term><term>Risk Factors</term><term>Time Factors</term><term>Treatment Outcome</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Abiraterone acetate (an androgen biosynthesis inhibitor) plus prednisone is approved for treating patients with metastatic castration-resistant prostate cancer (mCRPC). Study COU-AA-302 evaluated abiraterone acetate plus prednisone versus prednisone alone in mildly symptomatic or asymptomatic patients with progressive mCRPC without prior chemotherapy.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">24647231</PMID><DateCreated><Year>2015</Year><Month>02</Month><Day>02</Day></DateCreated><DateCompleted><Year>2015</Year><Month>11</Month><Day>02</Day></DateCompleted><DateRevised><Year>2016</Year><Month>12</Month><Day>15</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1873-7560</ISSN><JournalIssue CitedMedium="Internet"><Volume>66</Volume><Issue>5</Issue><PubDate><Year>2014</Year><Month>Nov</Month></PubDate></JournalIssue><Title>European urology</Title><ISOAbbreviation>Eur. Urol.</ISOAbbreviation></Journal><ArticleTitle>Updated interim efficacy analysis and long-term safety of abiraterone acetate in metastatic castration-resistant prostate cancer patients without prior chemotherapy (COU-AA-302).</ArticleTitle><Pagination><MedlinePgn>815-25</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.eururo.2014.02.056</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0302-2838(14)00185-7</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Abiraterone acetate (an androgen biosynthesis inhibitor) plus prednisone is approved for treating patients with metastatic castration-resistant prostate cancer (mCRPC). Study COU-AA-302 evaluated abiraterone acetate plus prednisone versus prednisone alone in mildly symptomatic or asymptomatic patients with progressive mCRPC without prior chemotherapy.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">Report the prespecified third interim analysis (IA) of efficacy and safety outcomes in study COU-AA-302.</AbstractText><AbstractText Label="DESIGN, SETTING, AND PARTICIPANTS" NlmCategory="METHODS">Study COU-AA-302, a double-blind placebo-controlled study, enrolled patients with mCRPC from April 2009 to June 2010. A total of 1088 patients were stratified by Eastern Cooperative Oncology Group performance status (0 vs 1).</AbstractText><AbstractText Label="INTERVENTION" NlmCategory="METHODS">Patients were randomised 1:1 to abiraterone 1000mg plus prednisone 5mg twice daily by mouth versus prednisone.</AbstractText><AbstractText Label="OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS" NlmCategory="METHODS">Co-primary end points were radiographic progression-free survival (rPFS) and overall survival (OS). Median times to event outcomes were estimated using the Kaplan-Meier method. Hazard ratios (HRs) and 95% confidence intervals (CIs) were derived using the Cox model, and treatment comparison used the log-rank test. The O'Brien-Fleming Lan-DeMets α-spending function was used for OS. Adverse events were summarised descriptively.</AbstractText><AbstractText Label="RESULTS AND LIMITATIONS" NlmCategory="CONCLUSIONS">With a median follow-up duration of 27.1 mo, improvement in rPFS was statistically significant with abiraterone treatment versus prednisone (median: 16.5 vs 8.2 mo; HR: 0.52 [95% CI, 0.45-0.61]; p<0.0001). Abiraterone improved OS (median: 35.3 vs 30.1 mo; HR: 0.79 [95% CI, 0.66-0.95]; p=0.0151) but did not reach the prespecified statistical efficacy boundary (α-level: 0.0035). A post hoc multivariate analysis for OS using known prognostic factors supported the primary results (HR: 0.74 [95% CI, 0.61-0.89]; p=0.0017), and all clinically relevant secondary end points and patient-reported outcomes improved. While the post hoc nature of the long-term safety analysis is a limitation, the safety profile with longer treatment exposure was consistent with prior reports.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The updated IA of study COU-AA-302 in patients with mCRPC without prior chemotherapy confirms that abiraterone delays disease progression, pain, and functional deterioration and has clinical benefit with a favourable safety profile, including in patients treated for ≥24 mo.</AbstractText><AbstractText Label="TRIAL REGISTRATION" NlmCategory="BACKGROUND">Study COU-AA-302, ClinicalTrials.gov number, NCT00887198.</AbstractText><AbstractText Label="PATIENT SUMMARY" NlmCategory="RESULTS">The updated results of this ongoing study showed that disease progression was delayed in patients with advanced prostate cancer who were treated with abiraterone acetate and prednisone, and there was a continued trend in prolongation of life compared with patients treated with prednisone alone. Treatment with abiraterone acetate and prednisone was well tolerated by patients who were treated for >2 yr.</AbstractText><CopyrightInformation>Copyright © 2014 European Association of Urology. Published by Elsevier B.V. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Rathkopf</LastName><ForeName>Dana E</ForeName><Initials>DE</Initials><AffiliationInfo><Affiliation>Memorial Sloan-Kettering Cancer Center and Weill Cornell Medical College, New York, NY, USA. Electronic address: rathkopd@mskcc.org.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Smith</LastName><ForeName>Matthew R</ForeName><Initials>MR</Initials><AffiliationInfo><Affiliation>Harvard Medical School and Massachusetts General Hospital, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>de Bono</LastName><ForeName>Johann S</ForeName><Initials>JS</Initials><AffiliationInfo><Affiliation>The Institute of Cancer Research and Royal Marsden NHS Foundation Trust, Sutton, Surrey, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Logothetis</LastName><ForeName>Christopher J</ForeName><Initials>CJ</Initials><AffiliationInfo><Affiliation>MD Anderson Cancer Center, Houston, TX, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shore</LastName><ForeName>Neal D</ForeName><Initials>ND</Initials><AffiliationInfo><Affiliation>Carolina Urologic Research Center, Atlantic Urology Clinics, Myrtle Beach, SC, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>de Souza</LastName><ForeName>Paul</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>University of Western Sydney School of Medicine, Penrith, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fizazi</LastName><ForeName>Karim</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Institut Gustave Roussy, University of Paris Sud, Villejuif, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mulders</LastName><ForeName>Peter F A</ForeName><Initials>PF</Initials><AffiliationInfo><Affiliation>Radboud University Medical Centre, Nijmegen, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mainwaring</LastName><ForeName>Paul</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Hematology & Oncology Clinics of Australia, Brisbane, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hainsworth</LastName><ForeName>John D</ForeName><Initials>JD</Initials><AffiliationInfo><Affiliation>Sarah Cannon Research Institute, Nashville, TN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Beer</LastName><ForeName>Tomasz M</ForeName><Initials>TM</Initials><AffiliationInfo><Affiliation>Oregon Health & Science University Knight Cancer Institute, Portland, OR, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>North</LastName><ForeName>Scott</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Cross Cancer Institute, Edmonton, Alberta, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fradet</LastName><ForeName>Yves</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Laval University, Québec City, Québec, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Van Poppel</LastName><ForeName>Hendrik</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>University Hospital Leuven, Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Carles</LastName><ForeName>Joan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Flaig</LastName><ForeName>Thomas W</ForeName><Initials>TW</Initials><AffiliationInfo><Affiliation>University of Colorado Cancer Center and University of Colorado School of Medicine, Aurora, CO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Efstathiou</LastName><ForeName>Eleni</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>MD Anderson Cancer Center, Houston, TX, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yu</LastName><ForeName>Evan Y</ForeName><Initials>EY</Initials><AffiliationInfo><Affiliation>University of Washington, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Higano</LastName><ForeName>Celestia S</ForeName><Initials>CS</Initials><AffiliationInfo><Affiliation>University of Washington, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Taplin</LastName><ForeName>Mary-Ellen</ForeName><Initials>ME</Initials><AffiliationInfo><Affiliation>Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Griffin</LastName><ForeName>Thomas W</ForeName><Initials>TW</Initials><AffiliationInfo><Affiliation>Janssen Research & Development, Los Angeles, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Todd</LastName><ForeName>Mary B</ForeName><Initials>MB</Initials><AffiliationInfo><Affiliation>Janssen Research & Development, Raritan, NJ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yu</LastName><ForeName>Margaret K</ForeName><Initials>MK</Initials><AffiliationInfo><Affiliation>Janssen Research & Development, Los Angeles, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Park</LastName><ForeName>Youn C</ForeName><Initials>YC</Initials><AffiliationInfo><Affiliation>Janssen Research & Development, Raritan, NJ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kheoh</LastName><ForeName>Thian</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Janssen Research & Development, Los Angeles, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Small</LastName><ForeName>Eric J</ForeName><Initials>EJ</Initials><AffiliationInfo><Affiliation>Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Scher</LastName><ForeName>Howard I</ForeName><Initials>HI</Initials><AffiliationInfo><Affiliation>Memorial Sloan-Kettering Cancer Center and Weill Cornell Medical College, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Molina</LastName><ForeName>Arturo</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Janssen Research & Development, Menlo Park, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ryan</LastName><ForeName>Charles J</ForeName><Initials>CJ</Initials><AffiliationInfo><Affiliation>Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Saad</LastName><ForeName>Fred</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>CRCHUM, University of Montréal, Montréal, Québec, Canada.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT00887198</AccessionNumber></AccessionNumberList></DataBank></DataBankList><GrantList CompleteYN="Y"><Grant><GrantID>K24 CA121990</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 CA008748</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 CA069533</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D017428">Clinical Trial, Phase III</PublicationType><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2014</Year><Month>03</Month><Day>06</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Eur Urol</MedlineTA><NlmUniqueID>7512719</NlmUniqueID><ISSNLinking>0302-2838</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000736">Androstenes</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018931">Antineoplastic Agents, Hormonal</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D065607">Cytochrome P-450 Enzyme Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.14.14.19</RegistryNumber><NameOfSubstance UI="D013254">Steroid 17-alpha-Hydroxylase</NameOfSubstance></Chemical><Chemical><RegistryNumber>EM5OCB9YJ6</RegistryNumber><NameOfSubstance UI="D000069501">Abiraterone Acetate</NameOfSubstance></Chemical><Chemical><RegistryNumber>VB0R961HZT</RegistryNumber><NameOfSubstance UI="D011241">Prednisone</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="Cites"><RefSource>Cancer J. 2013 Jan-Feb;19(1):43-9</RefSource><PMID Version="1">23337756</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>N Engl J Med. 2004 Oct 7;351(15):1502-12</RefSource><PMID Version="1">15470213</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>N Engl J Med. 2013 Jul 18;369(3):213-23</RefSource><PMID Version="1">23863050</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Lancet Oncol. 2013 Nov;14(12):1193-9</RefSource><PMID Version="1">24075621</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Eur J Cancer. 2013 Nov;49(17):3648-57</RefSource><PMID Version="1">23973186</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Eur Urol. 2014 Feb;65(2):467-79</RefSource><PMID Version="1">24321502</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Expert Opin Pharmacother. 2013 Jan;14(1):91-6</RefSource><PMID Version="1">23199349</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>N Engl J Med. 2004 Oct 7;351(15):1513-20</RefSource><PMID Version="1">15470214</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Clin Oncol. 1997 Jan;15(1):382-8</RefSource><PMID Version="1">8996165</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>BJU Int. 2005 Dec;96(9):1241-6</RefSource><PMID Version="1">16287438</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Clin Oncol. 2008 Jan 10;26(2):242-5</RefSource><PMID Version="1">18182665</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Clin Oncol. 2008 Mar 1;26(7):1148-59</RefSource><PMID Version="1">18309951</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Clin Oncol. 2009 Aug 10;27(23):3742-8</RefSource><PMID Version="1">19470933</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>N Engl J Med. 2010 Jul 29;363(5):411-22</RefSource><PMID Version="1">20818862</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Lancet. 2010 Oct 2;376(9747):1147-54</RefSource><PMID Version="1">20888992</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Urol. 2011 Mar;185(3):787-94</RefSource><PMID Version="1">21239012</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>N Engl J Med. 2011 May 26;364(21):1995-2005</RefSource><PMID Version="1">21612468</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Eur Urol. 2012 May;61(5):950-60</RefSource><PMID Version="1">22209376</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Cancer. 2012 May 15;118(10):2583-93</RefSource><PMID Version="1">22038761</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>N Engl J Med. 2012 Sep 27;367(13):1187-97</RefSource><PMID Version="1">22894553</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Lancet Oncol. 2012 Oct;13(10):983-92</RefSource><PMID Version="1">22995653</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Lancet Oncol. 2012 Dec;13(12):1210-7</RefSource><PMID Version="1">23142059</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>N Engl J Med. 2013 Jan 10;368(2):138-48</RefSource><PMID Version="1">23228172</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Ann Oncol. 2013 Apr;24(4):1017-25</RefSource><PMID Version="1">23152362</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Clin Oncol. 2003 Apr 1;21(7):1232-7</RefSource><PMID Version="1">12663709</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Eur Urol. 2014 Nov;66(5):826-8</RefSource><PMID Version="1">24751214</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000069501" MajorTopicYN="N">Abiraterone Acetate</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000736" MajorTopicYN="N">Androstenes</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018931" MajorTopicYN="N">Antineoplastic Agents, Hormonal</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000971" MajorTopicYN="N">Antineoplastic Combined Chemotherapy Protocols</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D065607" MajorTopicYN="N">Cytochrome P-450 Enzyme Inhibitors</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018572" MajorTopicYN="N">Disease-Free Survival</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004334" MajorTopicYN="N">Drug Administration Schedule</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053208" MajorTopicYN="N">Kaplan-Meier Estimate</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009362" MajorTopicYN="N">Neoplasm Metastasis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009376" MajorTopicYN="N">Neoplasms, Hormone-Dependent</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000201" MajorTopicYN="N">enzymology</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011241" MajorTopicYN="N">Prednisone</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016016" MajorTopicYN="N">Proportional Hazards Models</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D064129" MajorTopicYN="N">Prostatic Neoplasms, Castration-Resistant</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000201" MajorTopicYN="N">enzymology</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013254" MajorTopicYN="N">Steroid 17-alpha-Hydroxylase</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="Y">antagonists & inhibitors</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList><OtherID Source="NLM">NIHMS620764</OtherID><OtherID Source="NLM">PMC4418928</OtherID><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Abiraterone acetate</Keyword><Keyword MajorTopicYN="N">Chemotherapy-naive</Keyword><Keyword MajorTopicYN="N">Efficacy</Keyword><Keyword MajorTopicYN="N">Metastatic castration-resistant prostate cancer</Keyword><Keyword MajorTopicYN="N">Safety</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2013</Year><Month>12</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2014</Year><Month>02</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>3</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>3</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>11</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">24647231</ArticleId><ArticleId IdType="pii">S0302-2838(14)00185-7</ArticleId><ArticleId IdType="doi">10.1016/j.eururo.2014.02.056</ArticleId><ArticleId IdType="pmc">PMC4418928</ArticleId><ArticleId IdType="mid">NIHMS620764</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003365 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 003365 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:24647231
|texte= Updated interim efficacy analysis and long-term safety of abiraterone acetate in metastatic castration-resistant prostate cancer patients without prior chemotherapy (COU-AA-302).
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:24647231" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a AustralieFrV1
| This area was generated with Dilib version V0.6.33. |  |